Identifying the specific structural features of metallothionein that regulate its ability to modulate astrogliosis

该项目直接为指定的国家研究重点2做出贡献，并可能通过确定一种基于金属硫蛋白蛋白的新型和强大的治疗剂，潜在地对更广泛的澳大利亚社区产生重大影响，最终目的是帮助患有脑损伤或神经退行性疾病的患者。值得注意的是，UTAS和Bestenbalt LLC之间的合作是将这些令人兴奋的研究发现发展为澳大利亚生物技术行业和更广泛的澳大利亚社区具有商业可行性的结果的关键一步。

This project contributes directly to the Designated National Research Priority 2 and could potentially have a significant impact upon the broader Australian Community by identifying a novel and powerful therapeutic agent based upon metallothionein proteins with the ultimate aim of helping patients who have a brain injury or a neurodegenerative disease. It is important to note that the partnership between UTAS and Bestenbalt LLC is a critical step in the development of these exciting research discoveries into commercially viable outcomes for the Australian Biotechnology Industry and the broader Australian community.